1642297-01-5

Usage

Uses

GDC-0927, is a novel, non-steroidal, and selective estrogen receptor antagonist.

Upstream product

• 1352306-13-8 2-(4-iodophenyl)-4-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2H-chromene 
• 1352306-15-0 3-(3-hydroxyphenyl)-2-(4-iodophenyl)-4-methyl-2H-chromen-6-ol 
• 1352306-14-9 2-(4-iodophenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)chroman-4-one 
• 1352306-11-6 1-(2-hydroxy-5-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethanone 
• 1352306-12-7 1-(2,5-dihydroxyphenyl)-2-(3-hydroxyphenyl)ethanone 
• 1798-09-0 m-methoxyphenylacetic acid 
• 1097016-89-1 1-(2,5-dimethoxyphenyl)-2-(3-methoxyphenyl)ethanone 
• 6834-42-0 3-methoxyphenylacetic acid chloride 
• 1443983-86-5 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol 
• 17918-14-8 2,5-dimethoxybenzoyl chloride 
• 1146443-78-8 N,2,5-trimethoxy-N-methylbenzamide 
• 2785-98-0 2,5-dimethoxybenzoic acid 

Relevant academic research and scientific papers

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

The further optimization of ER-α degradation efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs). A fluoromethyl azetidine group was found to be preferred and resulted

ESTROGEN RECEPTOR MODULATOR AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in c